This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zheng, P. Articles by Liu, Y. Search for Related Content PubMed PubMed Citation Articles by Zheng, P. Articles by Liu, Y.

Two Mechanisms for Tumor Evasion of Preexisting Cytotoxic T-Cell Responses

Lessons from Recurrent Tumors¹

Department of Pathology and Comprehensive Cancer Center, Ohio State University Medical Center, Columbus, Ohio 43210

Tumors evade host immunity at both the induction and effector phases. Most studies have focused on tumor evasion at the induction phase, and, due in part to poor antitumor CTL responses to most tumors, the mechanism for evasion of CTL effector function is less clear. Here we have taken advantage of the strong CTL responses to a costimulator B7-1-transfected tumor to study the mechanism for tumor evasion of preexisting host immunity. We have investigated six independent recurrent tumors isolated from mice that were challenged with and had rejected B7-1-transfected J558 (J558-B7) tumors. Because the mice had developed strong antitumor CTL responses, these recurrent tumors must have evaded preexisting antitumor CTLs. Indeed, whereas the parental J558-B7 cell line is efficiently lysed by the ex vivo tumor-infiltrating lymphocytes, all of the recurrent tumors are resistant to such lysis. Interestingly, the recurrent tumors can be divided into two groups. The group 1 tumors have vastly reduced levels of cell surface MHC class I with a concurrent reduction in the expression of multiple genes devoted to MHC class I antigen presentation. In contrast, the group 2 tumors have lost the expression of costimulatory molecule B7-1 while retaining cell surface MHC class I and expression of all antigen presentation genes studied. These results demonstrate that tumors can evade preexisting CTLs either by avoiding presentation of the tumor antigen or, surprisingly, by down-regulation of costimulatory molecules. The paradoxical requirements of both antigen and costimulatory molecules at the effector phase raised an interesting question on the nature of antitumor immunity.

This article has been cited by other articles:

				L. Vago, S. K. Perna, M. Zanussi, B. Mazzi, C. Barlassina, M. T. L. Stanghellini, N. F. Perrelli, C. Cosentino, F. Torri, A. Angius, et al. Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation N. Engl. J. Med., July 30, 2009; 361(5): 478 - 488. [Abstract] [Full Text] [PDF]

				A. Liu, P. Hu, L. A. Khawli, and A. L. Epstein Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy Clin. Cancer Res., December 1, 2005; 11(23): 8492 - 8502. [Abstract] [Full Text] [PDF]

				W. Song and R. Levy Therapeutic Vaccination against Murine Lymphoma by Intratumoral Injection of Naive Dendritic Cells Cancer Res., July 1, 2005; 65(13): 5958 - 5964. [Abstract] [Full Text] [PDF]

				T. Yang, P. E. Lapinski, H. Zhao, Q. Zhou, H. Zhang, M. Raghavan, Y. Liu, and P. Zheng A Rare Transporter Associated with Antigen Processing Polymorphism Overpresented in HLAlow Colon Cancer Reveals the Functional Significance of the Signature Domain in Antigen Processing Clin. Cancer Res., May 15, 2005; 11(10): 3614 - 3623. [Abstract] [Full Text] [PDF]

				X. Zheng, J.-X. Gao, X. Chang, Y. Wang, Y. Liu, J. Wen, H. Zhang, J. Zhang, Y. Liu, and P. Zheng B7-CD28 Interaction Promotes Proliferation and Survival but Suppresses Differentiation of CD4-CD8- T Cells in the Thymus J. Immunol., August 15, 2004; 173(4): 2253 - 2261. [Abstract] [Full Text] [PDF]

				H. Tanaka, M. Yashiro, T. Sunami, Y. Sakate, K. Kosaka, and K. Hirakawa ICAM-2 Gene Therapy for Peritoneal Dissemination of Scirrhous Gastric Carcinoma Clin. Cancer Res., July 15, 2004; 10(14): 4885 - 4892. [Abstract] [Full Text] [PDF]

				S. Sarma, X.-F. Bai, J.-q. Liu, K. F. May Jr., P. Zheng, and Y. Liu On the Role of Unmutated Antigens in Tumor Rejection in Mice with Unperturbed T-cell Repertoires Cancer Res., September 15, 2003; 63(18): 6051 - 6055. [Abstract] [Full Text] [PDF]

				X. Liu, J. X. Gao, J. Wen, L. Yin, O. Li, T. Zuo, T. F. Gajewski, Y.-X. Fu, P. Zheng, and Y. Liu B7DC/PDL2 Promotes Tumor Immunity by a PD-1-independent Mechanism J. Exp. Med., June 16, 2003; 197(12): 1721 - 1730. [Abstract] [Full Text] [PDF]

				T. Yang, B. A. McNally, S. Ferrone, Y. Liu, and P. Zheng A Single-nucleotide Deletion Leads to Rapid Degradation of TAP-1 mRNA in a Melanoma Cell Line J. Biol. Chem., April 18, 2003; 278(17): 15291 - 15296. [Abstract] [Full Text] [PDF]

				R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner J. Immunol., August 15, 2002; 169(4): 1792 - 1800. [Abstract] [Full Text] [PDF]

				X. Liu, X.-F. Bai, J. Wen, J.-X. Gao, J. Liu, P. Lu, Y. Wang, P. Zheng, and Y. Liu B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo J. Exp. Med., November 5, 2001; 194(9): 1339 - 1348. [Abstract] [Full Text] [PDF]

				X.-F. Bai, J.-X. Gao, J. Liu, J. Wen, P. Zheng, and Y. Liu On the Site and Mode of Antigen Presentation for the Initiation of Clonal Expansion of CD8 T Cells Specific for a Natural Tumor Antigen Cancer Res., September 1, 2001; 61(18): 6860 - 6867. [Abstract] [Full Text] [PDF]

				Y. Guilloux, X.-f. Bai, X. Liu, P. Zheng, and Y. Liu Optimal Induction of Effector but not Memory Antitumor Cytotoxic T Lymphocytes Involves Direct Antigen Presentation by the Tumor Cells Cancer Res., February 1, 2001; 61(3): 1107 - 1112. [Abstract] [Full Text]

				M. Maric and Y. Liu Strong Cytotoxic T Lymphocyte Responses to a Macrophage Inflammatory Protein 1{{alpha}}-expressing Tumor: Linkage between Inflammation and Specific Immunity Cancer Res., November 1, 1999; 59(21): 5549 - 5553. [Abstract] [Full Text] [PDF]